Cronos Group Initiates Share Repurchase Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Repurchase Program Launch: Cronos Group has filed a notice of intention for a normal course issuer bid with the Toronto Stock Exchange, which has been accepted, indicating the company's confidence in its stock value as the program commenced on May 14, 2026, and is expected to end on May 13, 2027.
- Repurchase Scale: The company intends to repurchase up to $50 million of common shares, representing approximately 5.02% of its 373 million issued shares, which is expected to enhance earnings per share and improve shareholder returns.
- Trading Flexibility: Cronos can execute repurchases through various trading systems, including NASDAQ and other U.S. markets, with a daily limit of 53,968 shares on the TSX, demonstrating its operational flexibility in capital management.
- Regulatory Exemption: The company received an exemption from the Ontario Securities Commission, allowing it to repurchase shares on U.S. markets beyond the limits set by Canadian law, further strengthening its capital management strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRON
Wall Street analysts forecast CRON stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.670
Low
2.30
Averages
2.72
High
3.14
Current: 2.670
Low
2.30
Averages
2.72
High
3.14
About CRON
Cronos Group Inc. is a global cannabinoid company engaged in building disruptive intellectual property by advancing cannabis research, technology and product development. The Company's diverse international brand portfolio includes Spinach, PEACE NATURALS and Lord Jones. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, edibles and tinctures. Lord Jones is a premium adult-use cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer and edible categories. Lord Jones Ice Water Hash Fusions pre-rolls feature flower and terpene-rich ice water hash and are fitted with a branded ceramic tip. PEACE NATURALS is a global medical brand engaged in producing cannabis products. The Company distributes products under the PEACE NATURALS brand for the Canadian market and the Israeli, German, and United Kingdom medical markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cronos Group Initiates Share Repurchase Program
- Repurchase Program Launch: Cronos Group has filed a notice of intention for a normal course issuer bid with the Toronto Stock Exchange, which has been accepted, indicating the company's confidence in its stock value as the program commenced on May 14, 2026, and is expected to end on May 13, 2027.
- Repurchase Scale: The company intends to repurchase up to $50 million of common shares, representing approximately 5.02% of its 373 million issued shares, which is expected to enhance earnings per share and improve shareholder returns.
- Trading Flexibility: Cronos can execute repurchases through various trading systems, including NASDAQ and other U.S. markets, with a daily limit of 53,968 shares on the TSX, demonstrating its operational flexibility in capital management.
- Regulatory Exemption: The company received an exemption from the Ontario Securities Commission, allowing it to repurchase shares on U.S. markets beyond the limits set by Canadian law, further strengthening its capital management strategy.
See More
Trulieve Becomes First U.S. Cannabis Company Listed on NYSE
- Historic Listing: Trulieve successfully listed on the NYSE on June 10, becoming the first U.S. cannabis company on a major exchange, marking a significant milestone for the U.S. cannabis industry and likely attracting increased investor interest.
- Financial Performance: In its first quarter, Trulieve reported $100 million in adjusted EBITDA, while Tilray expects EBITDA between $62 million and $72 million for the year, highlighting Trulieve's superior profitability.
- Market Competition: Trulieve and Tilray now compete directly on major exchanges; although Tilray has a broader international presence, Trulieve's vertically integrated model provides better resilience against price fluctuations in the U.S. market.
- Tax Relief: With the U.S. rescheduling medical marijuana to Schedule III, Trulieve stands to benefit from reduced 280E tax burdens, significantly improving its financial outlook and reinforcing its market position.
See More
Trulieve Lists on NYSE, Competes with Tilray
- Listing Achievement: Trulieve began trading on the NYSE on June 10, becoming the first U.S. cannabis company to list on a major exchange, marking a significant milestone for the U.S. cannabis industry and potentially attracting more investor interest.
- Financial Performance Comparison: Trulieve reported $100 million in adjusted EBITDA for Q1, while Tilray expects EBITDA between $62 million and $72 million this year, highlighting Trulieve's clear advantage in profitability.
- Market Competition Landscape: With 240 dispensaries, Trulieve's operational model allows it to capture the entire retail markup, whereas Tilray, primarily a wholesale manufacturer, faces greater pricing pressure, resulting in significantly lower profit margins compared to Trulieve.
- Tax Policy Impact: The U.S. reclassification of medical marijuana to Schedule III alleviates Trulieve's 280E tax burden, which is expected to yield substantial financial benefits, further solidifying its leadership position in the market.
See More
Cronos' Spinach® Becomes Top-Selling Vape Brand in Canada
- Market Share Leadership: Cronos Group's Spinach® vape captured 10.4% of the Canadian vape market in April 2026, maintaining this leading position since January 2026, demonstrating strong consumer appeal and loyalty.
- Innovation-Driven Products: Spinach® vapes utilize high-purity extracts and advanced hardware to deliver high-quality, flavorful, and consistent experiences for adult consumers, further solidifying its competitive edge in the rapidly growing vape market.
- New Product Launches: The brand plans to introduce several new SKUs this summer, including three new flavors for the Spinach PUFFERZ™ all-in-one vape and its first limited-time offer Orange Vanilla Twist vape, which is expected to drive sales growth and attract new customers.
- Global Expansion Strategy: CEO Mike Gorenstein emphasized that Spinach®'s success in Canada validates the effectiveness of its product innovation engine and builds confidence for future expansion of cannabinoid products globally.
See More
DEA Hearing on Marijuana Rescheduling Sparks Market Optimism
- Hearing Date Set: The DEA is scheduled to hold a hearing on June 29 to discuss reclassifying marijuana from Schedule I to Schedule III, which could significantly impact commercial and medical uses across the country.
- Trump Administration Pushes Legislation: The Trump administration is urging Congress to amend the broad ban on hemp-derived products to ensure the legality of CBD products, which is expected to benefit farmers and further fuel market optimism for cannabis stocks.
- Positive Market Reaction: Following this news, shares of Tilray Brands (TLRY) rose nearly 4% in premarket trading, making it the top-trending ticker on Stocktwits, while peers like Canopy Growth (CGC), Aurora Cannabis (ACB), and Cronos (CRON) also saw their stock prices increase.
- Investor Sentiment Shift: On Stocktwits, retail sentiment regarding TLRY shifted from 'bullish' to 'extremely bullish', indicating high expectations for the upcoming DEA hearing, which could potentially alter the sentiment curve in the market.
See More
Andrew Left Convicted of Stock Manipulation Charges
- Stock Manipulation Conviction: A Los Angeles jury found Andrew Left guilty on 13 counts of stock manipulation between 2018 and 2023, highlighting the severity of his actions in leveraging social media influence for market manipulation, which could result in millions in fines and restitution.
- Profit Details: Prosecutors revealed that Left earned over $20 million by making bold stock calls on social media while secretly executing opposite trades, raising concerns about market fairness and increasing scrutiny on short sellers from regulators.
- Citron Research's Response: Following the conviction, Citron Research expressed dissatisfaction with the jury's ruling, arguing that the case could deter honest commentary from investors and market analysts, and pledged to continue fighting for free speech, indicating a commitment to ongoing legal battles.
- Impact of GameStop Incident: Left's bearish stance on GameStop in 2021 sparked significant retail trading activity; despite the conviction potentially tarnishing his reputation, he plans to short GameStop again in 2024, demonstrating his ongoing engagement with market dynamics.
See More
Cronos Group Initiates Share Repurchase Program
- Repurchase Program Launch: Cronos Group has filed a notice of intention for a normal course issuer bid with the Toronto Stock Exchange, which has been accepted, indicating the company's confidence in its stock value as the program commenced on May 14, 2026, and is expected to end on May 13, 2027.
- Repurchase Scale: The company intends to repurchase up to $50 million of common shares, representing approximately 5.02% of its 373 million issued shares, which is expected to enhance earnings per share and improve shareholder returns.
- Trading Flexibility: Cronos can execute repurchases through various trading systems, including NASDAQ and other U.S. markets, with a daily limit of 53,968 shares on the TSX, demonstrating its operational flexibility in capital management.
- Regulatory Exemption: The company received an exemption from the Ontario Securities Commission, allowing it to repurchase shares on U.S. markets beyond the limits set by Canadian law, further strengthening its capital management strategy.
See More
Trulieve Becomes First U.S. Cannabis Company Listed on NYSE
- Historic Listing: Trulieve successfully listed on the NYSE on June 10, becoming the first U.S. cannabis company on a major exchange, marking a significant milestone for the U.S. cannabis industry and likely attracting increased investor interest.
- Financial Performance: In its first quarter, Trulieve reported $100 million in adjusted EBITDA, while Tilray expects EBITDA between $62 million and $72 million for the year, highlighting Trulieve's superior profitability.
- Market Competition: Trulieve and Tilray now compete directly on major exchanges; although Tilray has a broader international presence, Trulieve's vertically integrated model provides better resilience against price fluctuations in the U.S. market.
- Tax Relief: With the U.S. rescheduling medical marijuana to Schedule III, Trulieve stands to benefit from reduced 280E tax burdens, significantly improving its financial outlook and reinforcing its market position.
See More
Trulieve Lists on NYSE, Competes with Tilray
- Listing Achievement: Trulieve began trading on the NYSE on June 10, becoming the first U.S. cannabis company to list on a major exchange, marking a significant milestone for the U.S. cannabis industry and potentially attracting more investor interest.
- Financial Performance Comparison: Trulieve reported $100 million in adjusted EBITDA for Q1, while Tilray expects EBITDA between $62 million and $72 million this year, highlighting Trulieve's clear advantage in profitability.
- Market Competition Landscape: With 240 dispensaries, Trulieve's operational model allows it to capture the entire retail markup, whereas Tilray, primarily a wholesale manufacturer, faces greater pricing pressure, resulting in significantly lower profit margins compared to Trulieve.
- Tax Policy Impact: The U.S. reclassification of medical marijuana to Schedule III alleviates Trulieve's 280E tax burden, which is expected to yield substantial financial benefits, further solidifying its leadership position in the market.
See More
Cronos' Spinach® Becomes Top-Selling Vape Brand in Canada
- Market Share Leadership: Cronos Group's Spinach® vape captured 10.4% of the Canadian vape market in April 2026, maintaining this leading position since January 2026, demonstrating strong consumer appeal and loyalty.
- Innovation-Driven Products: Spinach® vapes utilize high-purity extracts and advanced hardware to deliver high-quality, flavorful, and consistent experiences for adult consumers, further solidifying its competitive edge in the rapidly growing vape market.
- New Product Launches: The brand plans to introduce several new SKUs this summer, including three new flavors for the Spinach PUFFERZ™ all-in-one vape and its first limited-time offer Orange Vanilla Twist vape, which is expected to drive sales growth and attract new customers.
- Global Expansion Strategy: CEO Mike Gorenstein emphasized that Spinach®'s success in Canada validates the effectiveness of its product innovation engine and builds confidence for future expansion of cannabinoid products globally.
See More
DEA Hearing on Marijuana Rescheduling Sparks Market Optimism
- Hearing Date Set: The DEA is scheduled to hold a hearing on June 29 to discuss reclassifying marijuana from Schedule I to Schedule III, which could significantly impact commercial and medical uses across the country.
- Trump Administration Pushes Legislation: The Trump administration is urging Congress to amend the broad ban on hemp-derived products to ensure the legality of CBD products, which is expected to benefit farmers and further fuel market optimism for cannabis stocks.
- Positive Market Reaction: Following this news, shares of Tilray Brands (TLRY) rose nearly 4% in premarket trading, making it the top-trending ticker on Stocktwits, while peers like Canopy Growth (CGC), Aurora Cannabis (ACB), and Cronos (CRON) also saw their stock prices increase.
- Investor Sentiment Shift: On Stocktwits, retail sentiment regarding TLRY shifted from 'bullish' to 'extremely bullish', indicating high expectations for the upcoming DEA hearing, which could potentially alter the sentiment curve in the market.
See More
Andrew Left Convicted of Stock Manipulation Charges
- Stock Manipulation Conviction: A Los Angeles jury found Andrew Left guilty on 13 counts of stock manipulation between 2018 and 2023, highlighting the severity of his actions in leveraging social media influence for market manipulation, which could result in millions in fines and restitution.
- Profit Details: Prosecutors revealed that Left earned over $20 million by making bold stock calls on social media while secretly executing opposite trades, raising concerns about market fairness and increasing scrutiny on short sellers from regulators.
- Citron Research's Response: Following the conviction, Citron Research expressed dissatisfaction with the jury's ruling, arguing that the case could deter honest commentary from investors and market analysts, and pledged to continue fighting for free speech, indicating a commitment to ongoing legal battles.
- Impact of GameStop Incident: Left's bearish stance on GameStop in 2021 sparked significant retail trading activity; despite the conviction potentially tarnishing his reputation, he plans to short GameStop again in 2024, demonstrating his ongoing engagement with market dynamics.
See More
